NASDAQ:SCLX
READ THE FULL SCLX RESEARCH REPORT
Scilex Holding Company (NASDAQ:SCLX) is a revenue-generating company that is focused on addressing one of the biggest issues facing humanity today—that of the overuse of opioids. Scilex is focused on developing non-opioid pain management products that provide the relief patients so desperately need, while avoiding the debilitating addiction that often comes with the use of opioids. Roughly 112,000 Americans died in 2023 from overdoses and there we have no doubt that a good number of those involved opioid use at some point to reduce physical pain of various types.
Scilex continues to grow its product offerings and distribution channels, leading to more patients being helped and more revenue coming in.
The company recently released its 2Q2024 results that showed a great improvement in revenue that blew past our estimates and vastly outpaced 1Q results. The net revenue number of $16.4 million was driven by a 16% increase in sales of its ZTlido treatment and a 49% gain in sales of ELYXYB along with the introduction in 2Q of its treatment for gout—GLOPERBA.
As a reminder, gout is a painful arthritic disorder that affects an estimated 9.2 million people in the United States. Gloperba has the chance to have a major impact on many of these patients as it is the first and only liquid oral version of the anti-gout medicine colchicine. According to data collected by the company, over 70% of gout patients have comorbid conditions that may require dose adjustments and could benefit from Gloperba. Additionally, over 17% of patients on colchicine experience severe gastrointestinal side effects and also may benefit from the flexible dosing offered by Gloperba. A recent market research study among rheumatologists conducted by Scilex revealed a high degree of interest in Gloperba as a liquid colchicine formulation designed for precision dosing.5 Specifically, clinicians using colchicine for prophylaxis of gout flares in adults indicated a strong likelihood to use Gloperba instead of tablets/capsules in certain at-risk patient populations who have a clinical need for lowered precision dosing to mitigate the risk of colchicine toxicity.
As a result of the increase in revenue and successful launch of GLOPERBA and our belief that the products of Scilex are gaining increasing traction and that sales growth will accelerate as more patients become aware of the benefits, we are raising our price target to $5.50 per share.
These announcements and plans for the future reinforce our belief that SCLX is poised to resume its move higher and that investors continue to underestimate the value of treatments the company currently has and is developing. We urge investors to take a look at a company that is earning revenue, growing that revenue in a meaningful way, and adding to its portfolio of very important treatments before the rest of the investing community realizes the story developing at Scilex.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.
